TICKERNERD
Menu
PRFXPRFXHealthcare · Drug Manufacturers - Specialty & Generic

PRFX Stock Forecast: PRF Technologies Ltd. Price Predictions for 2026-2027

Last close, 31 July 2026
$1.00

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$3.0M
Ticker Nerd rank
3 / 100
Median analyst target
—
Analysts covering
1
Ticker Nerd rank

PRFX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PRF Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Revisions
25
Accruals
24
Momentum
22
Issuance
15
Volatility
1
Quality
0
Value
0
Growth
0

Size (98): Smaller than most of the companies we track.

Growth (0): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own PRF Technologies Ltd. — and when they’d sell — is the membership.

Wall Street

PRFX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRFX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Oct 2024Maxim GroupDowngradeHold—
26 June 2024Maxim GroupReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PRFX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

PRF Technologies Ltd. (PRFX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 73% of US stocks

Price / sales
178.9×

Cheaper than 3% of US stocks

Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
0.6×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−16200.0%

Higher than 1% of US stocks

Net margin
−311.8%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−90.4%

Higher than 14% of US stocks

Return on assets
−38.7%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PRFX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PRFXPRF Technologies Ltd.$3.0M
3
SBFMSunshine Biopharma, Inc.$2.8M
43
SHPHShuttle Pharmaceuticals Holdings, Inc.$2.4M
16
UPCUniverse Pharmaceuticals, Inc.$2.0M
29
SXTCChina Sxt Pharmaceuticals, Inc.$2.0M
8
INMInMed Pharmaceuticals, Inc.$4.9M
22
YCBDcbdMD, Inc.$5.1M
49
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRFX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest PRFX news & analysis

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

GlobeNewsWire · 27 July 2026positive

PRF Technologies' interim CEO Efraim Cohen-Arazi issued a letter to shareholders detailing the company's strengthened financial position, including $10 million in new capital, and provided updates on LayerBio's preparations for a planned Phase 2 clinical trial of OcuRing™-K and DeepSolar's progress toward commercial launch.

Why it matters — The letter updates shareholders on the company's improved financial standing and progress across both its biotechnology and AI-driven energy divisions.

FAQ

Frequently asked questions about PRFX stock

Is PRFX stock a buy right now?

Of the 1 analysts covering PRF Technologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PRF Technologies Ltd. 3 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRFX?

As at 1 Aug 2026, PRF Technologies Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the PRFX stock forecast for 2030?

No analyst covering PRF Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRFX are extrapolating price history, which says nothing about the business.

What does PRF Technologies Ltd. do?

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for surgical and post-operative pain management.

What is the latest news on PRFX?

The most recent item we track (GlobeNewsWire, 27 July 2026): "PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms". PRF Technologies' interim CEO Efraim Cohen-Arazi issued a letter to shareholders detailing the company's strengthened financial position, including $10 million in new capital, and provided updates on LayerBio's preparations for a planned Phase 2 clinical trial of OcuRing™-K and DeepSolar's progress toward commercial launch.

Company

About PRF Technologies Ltd.

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for surgical and post-operative pain management. Its core product, PRF-110, is designed as an oil-based, viscous solution applied directly into the surgical wound bed before closure to provide localized and extended analgesia. The company’s work centers on improving drug delivery in areas where sustained pain control and targeted treatment are important, particularly in hospital-based surgical settings. PainReform Ltd. operates in the healthcare and drug development sectors, where it contributes to the development of specialized treatment options built around existing active ingredients and delivery technologies. Headquartered in Israel, the company remains focused on advancing products intended for post-operative care and other clinical applications.

CEO Mr. Efraim Cohen-Arazi · 6 employees · Israel · https://www.painreform.com